{"product_id":"cyth-vrio-analysis","title":"Cyclo Therapeutics, Inc. (CYTH): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking sustainable competitive advantage for Cyclo Therapeutics, Inc. (CYTH) hinges on its core resources. This VRIO analysis cuts straight to the chase, assessing the Value, Rarity, Inimitability, and Organization that define its market power. Read on to see the crucial findings that determine if Cyclo Therapeutics, Inc. (CYTH) is built to last.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: Proprietary Drug Candidate: Trappsol® Cyclo™ (Cyclodextrin-based Therapy)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou are looking at the core asset for Cyclo Therapeutics, Inc., Trappsol® Cyclo™, and trying to figure out if it's a true moat or just a temporary lead. Honestly, for a rare disease like Niemann-Pick Type C (NPC1), the entire game hinges on this one molecule.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Addressing a Fatal Unmet Need\u003c\/h3\u003e\n\u003cp\u003eThe drug candidate is valuable because it targets the root cause of NPC1 - mobilizing lysosomal cholesterol - in a disease where there is no approved therapy in the United States and only one in Europe. Cyclo Therapeutics, Inc. has secured significant regulatory tailwinds, including \u003cstrong\u003eOrphan Drug Designation\u003c\/strong\u003e in both the US and EU, plus \u003cstrong\u003eFast Track\u003c\/strong\u003e and \u003cstrong\u003eRare Pediatric Disease Designation\u003c\/strong\u003e (RPDD) from the FDA. The RPDD is key; it means a Priority Review Voucher can be earned upon approval, which is a major financial lever. The Phase 3 TransportNPC™ trial, which completed enrollment of \u003cstrong\u003e104 patients\u003c\/strong\u003e in May 2024, is the proof point. Preliminary data from the sub-study in children under 3 showed \u003cstrong\u003e86%\u003c\/strong\u003e (6 of 7 patients) maintained stabilization or improvement at 48 weeks on the CGI-C scale. If the main 48-week interim analysis, expected in H1 2025, validates this, the value proposition is immense.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Unique Application, Known Chemistry\u003c\/h3\u003e\n\u003cp\u003eHere’s the nuance: the active ingredient, hydroxypropyl-beta-cyclodextrin, is known chemistry. That’s not rare. What is rare is this \u003cstrong\u003especific formulation\u003c\/strong\u003e and its proven ability to cross the blood-brain barrier after intravenous administration, targeting the central nervous system effects of NPC1. The rarity comes from the specific clinical package built around this application for this indication. It’s not just the ingredient; it’s the dossier and the regulatory pathway that are scarce right now for NPC1 patients.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: The Cost of Replication\u003c\/h3\u003e\n\u003cp\u003eReplicating Trappsol® Cyclo™ is tough, not because the chemistry is secret, but because of the time and capital sunk into the clinical pathway. A competitor would need to replicate years of work, including the ongoing, fully enrolled Phase 3 TransportNPC™ trial. They would also need to overcome the regulatory head start Cyclo Therapeutics, Inc. has with its existing designations. If the topline data in H2 2025 is positive, leading to an NDA submission, the time lag alone creates a significant barrier. It’s defintely hard to copy a drug that is already 96 weeks into a pivotal trial.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Singular Focus and Financial Strain\u003c\/h3\u003e\n\u003cp\u003eThe organization is highly focused; the entire R\u0026amp;D effort is channeled into Trappsol® Cyclo™ for NPC1, maximizing resource concentration. However, this focus comes with financial pressure. For the third quarter ending September 30, 2024, Cyclo Therapeutics, Inc. reported a net loss of approximately \u003cstrong\u003e$8.8 million\u003c\/strong\u003e, with Research and development expenses at about \u003cstrong\u003e$5.5 million\u003c\/strong\u003e for that quarter. The cash position at that time was lean, ending the quarter with only about \u003cstrong\u003e$0.9 million\u003c\/strong\u003e. This lean structure means the company is critically dependent on the successful H1 2025 data readout to secure further funding or achieve market authorization, which is the ultimate organizational goal. They are organized around a single, high-stakes catalyst.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick summary of the VRIO assessment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment for Trappsol® Cyclo™\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes. Addresses fatal, unmet need; regulatory incentives (RPDD, ODD).\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity or Temporary Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes. Specific IV formulation with CNS penetration data for NPC1.\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly. Years of clinical data and regulatory progress (Phase 3 enrolled).\u003c\/td\u003e\n\u003ctd\u003ePotential for Sustained Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eHigh focus, but cash position (approx. \u003cstrong\u003e$0.9 million\u003c\/strong\u003e as of Q3 2024) requires immediate success.\u003c\/td\u003e\n\u003ctd\u003ePotential for Sustained Competitive Advantage (Pending Data)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe competitive advantage is currently sitting on a knife’s edge. It’s a \u003cstrong\u003ePotential Sustained Competitive Advantage\u003c\/strong\u003e, but that hinges entirely on the Phase 3 data validation in 2025. If the data is positive, the combination of regulatory exclusivity and clinical lead creates a strong moat.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eData readout expected: H1 2025.\u003c\/li\u003e\n\u003cli\u003eNDA\/MAA submission targeted: H2 2025.\u003c\/li\u003e\n\u003cli\u003eSub-study success: \u003cstrong\u003e86%\u003c\/strong\u003e improvement\/stabilization at 48 weeks.\u003c\/li\u003e\n\u003cli\u003e2023 Annual Loss: \u003cstrong\u003e$20.06 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: Prepare a 13-week cash flow forecast incorporating potential milestone payments or financing needs post-H1 2025 data release by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: Phase 3 Clinical Data Readout (TransportNPC™ Interim Analysis)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eTrial Metrics Summary\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Enrolled Patients (TransportNPC™)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e104\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubstudy Enrollment (\u0026lt; 3 Years)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Completion Date\u003c\/td\u003e\n\u003ctd\u003eMay 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterim Analysis Data Readout Target\u003c\/td\u003e\n\u003ctd\u003eH1 2025 \/ Mid-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNDA\/MAA Submission Target\u003c\/td\u003e\n\u003ctd\u003eH2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Duration (Blinded Phase)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e96\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint (EU)\u003c\/td\u003e\n\u003ctd\u003eChange in \u003cstrong\u003e5D-NPC-CSS\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage ASIS at Recruitment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.04\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Age at Inclusion\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20.2\u003c\/strong\u003e years (Range: \u003cstrong\u003e3\u003c\/strong\u003e – \u003cstrong\u003e65\u003c\/strong\u003e years)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nMid-2025 data readout is the critical inflection point for potential NDA submission in H2 2025 and commercial viability.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSubstudy CGI-C Stabilization\/Improvement at \u003cstrong\u003e24\u003c\/strong\u003e weeks: \u003cstrong\u003e87%\u003c\/strong\u003e (\u003cstrong\u003e7 of 8\u003c\/strong\u003e patients)\u003c\/li\u003e\n\u003cli\u003eSubstudy CGI-C Stabilization\/Improvement at \u003cstrong\u003e48\u003c\/strong\u003e weeks: \u003cstrong\u003e86%\u003c\/strong\u003e (\u003cstrong\u003e6 of 7\u003c\/strong\u003e patients)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nA fully enrolled, controlled Phase 3 trial in a rare disease is a significant, hard-won asset.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eTotal Adverse Events (AEs) Reported: \u003cstrong\u003e625\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAE Severity Breakdown: Grade 1: \u003cstrong\u003e80%\u003c\/strong\u003e; Grade 2: \u003cstrong\u003e16.7%\u003c\/strong\u003e; Grade 3: \u003cstrong\u003e5.3%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSerious Adverse Events (SAEs) Reported: \u003cstrong\u003e9\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePatient Withdrawals due to Safety: \u003cstrong\u003e0\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe trial execution and the resulting data set are inimitable once generated.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial\/Operational Data\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e$8.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 R\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e$5.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense Increase (YoY Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e57%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand (End of Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e$0.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin (LTM Q2 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e91.56%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe team executed enrollment completion in May 2024, showing strong operational focus leading up to the readout.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eConvertible Note Secured (March 2025)\u003c\/li\u003e\n\u003cli\u003eTotal Convertible Debt from Rafael Holdings since June 11, 2024: \u003cstrong\u003e$18 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eLatest Convertible Note Interest Rate: \u003cstrong\u003e5%\u003c\/strong\u003e annual\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary, as the advantage shifts to commercial execution post-positive data.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eQualification for Priority Review Voucher expected upon NDA submission\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: Orphan Drug Designation (NPC1)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOrphan Drug Designation (NPC1)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eMarket exclusivity post-approval: 7 years in the US, 10 years in the EU. The Rare Pediatric Disease Designation (RPDD) in the U.S. is a chief requirement for sponsors to receive a Priority Review Voucher (PRV) upon marketing authorization.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe designation applies to Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The pivotal Phase 3 TransportNPC™ study has 104 enrolled patients.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eRegulatory designations are granted by agencies and cannot be imitated; they are earned. The company has secured Orphan Drug Designation in the U.S. and EU, along with Fast Track and RPDD in the U.S.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe company successfully navigated the regulatory pathway to secure this status early on. Key milestones achieved include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnrollment completion in the Phase 3 TransportNPC™ trial.\u003c\/li\u003e\n\u003cli\u003eTargeting NDA and MAA submissions in 2H 2025 if 48-week data demonstrates significance.\u003c\/li\u003e\n\u003cli\u003eTopline data from the 48-week interim analysis expected in H1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company reported a net loss of $8.8 million for Q3 2024, with Research and development expenses of approximately $5.5 million for the same period. Cash position at the end of Q3 2024 was approximately $0.9 million.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSustained, as long as the designation remains valid post-approval. Preliminary data from the open-label sub-study showed:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003ePatient Count\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStabilization\/Improvement at 24 Weeks (Sub-study)\u003c\/td\u003e\n\u003ctd\u003e87%\u003c\/td\u003e\n\u003ctd\u003e7 of 8 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStabilization\/Improvement at 48 Weeks (Sub-study)\u003c\/td\u003e\n\u003ctd\u003e86%\u003c\/td\u003e\n\u003ctd\u003e6 of 7 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company is targeting qualification for a Priority Review Voucher upon NDA submission.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: Intellectual Property Estate (Alzheimer's Disease Claims)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eIntellectual Property Estate (Alzheimer's Disease Claims)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides optionality and potential diversification by covering use in a massive indication like early Alzheimer's disease. The US market for Alzheimer's disease (AD) is estimated to be approximately 5.5 million patients, with the global cost of AD and other forms of dementia estimated at $605 billion currently.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The granted US Patent No. 11,925,659 for AD treatment is a specific, defensible legal asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Patents offer strong, legally enforced barriers to imitation for the claimed methods.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The IP team secured key patents, building a moat around the core technology beyond NPC1. The Company is conducting a Phase 2b clinical trial for early AD (NCT05607615).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the patents remain in force.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key intellectual property and associated quantitative data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAttribute\u003c\/th\u003e\n\u003cth\u003eUS Patent (No. 11,925,659)\u003c\/th\u003e\n\u003cth\u003eEuropean Patent (No. 3873604B)\u003c\/th\u003e\n\u003cth\u003eProduct Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitle\u003c\/td\u003e\n\u003ctd\u003eMethods for Treating Alzheimer's Disease\u003c\/td\u003e\n\u003ctd\u003eMethods for Treating Alzheimer's Disease\u003c\/td\u003e\n\u003ctd\u003eTrappsol® Cyclo™\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrant\/Allowance Date\u003c\/td\u003e\n\u003ctd\u003eMarch 12, 2024\u003c\/td\u003e\n\u003ctd\u003eEffective August 21, 2024\u003c\/td\u003e\n\u003ctd\u003eOrphan Drug Designation (US \u0026amp; Europe)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpiration Year (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2040\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-grant term applies\u003c\/td\u003e\n\u003ctd\u003eIn Phase 2b Clinical Trial (AD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe scope of the AD claims includes specific technical parameters and patient populations:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe composition may comprise a mixture of two or more hydroxypropyl-beta-cyclodextrin species with a molar substitution value from about 0.59 to about 0.73.\u003c\/li\u003e\n\u003cli\u003eContemplated parenteral dose amounts range from 500 mg\/kg to 3000 mg\/kg.\u003c\/li\u003e\n\u003cli\u003eContemplated CNS directed administration dose amounts range from 100 mg to 750 mg.\u003c\/li\u003e\n\u003cli\u003eThe patent covers treatment of early onset Alzheimer's disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context related to operations supporting IP development:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the three months ended September 30, 2024, were approximately $5.5 million.\u003c\/li\u003e\n\u003cli\u003eNet loss for the quarter ended September 30, 2024, was approximately $8.8 million.\u003c\/li\u003e\n\u003cli\u003eCash on hand at the end of Q3 2024 was approximately $0.9 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: Completed Phase 3 Trial Infrastructure (TransportNPC™)\n\u003c\/h2\u003e\n\u003ch\u003eCompleted Phase 3 Trial Infrastructure (TransportNPC™)\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates the capability to manage a complex, multi-center, global pivotal trial, which is a major operational hurdle cleared.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e For a company of its size, successfully completing enrollment in a pivotal rare disease trial is not common. The disease affects approximately \u003cstrong\u003e1 in 100,000\u003c\/strong\u003e live births globally.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The established site relationships, patient recruitment network, and trial SOPs are difficult to replicate quickly. The infrastructure supported a study across \u003cstrong\u003e13 countries\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The team achieved full enrollment by \u003cstrong\u003eMay 2024\u003c\/strong\u003e, showing effective project management under prior constraints. Research and development expenses increased \u003cstrong\u003e57%\u003c\/strong\u003e to approximately \u003cstrong\u003e$5.5 million\u003c\/strong\u003e for the three months ended September 30, 2024, compared to approximately \u003cstrong\u003e$3.5 million\u003c\/strong\u003e for the same period in 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the infrastructure is only valuable until the next trial starts or is fully absorbed by the parent company. The Company ended Q2 2024 with approximately \u003cstrong\u003e$1.1 million\u003c\/strong\u003e of cash.\u003c\/p\u003e\n\u003cp\u003eThe scope of the completed infrastructure is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal Trial Patients Enrolled (TransportNPC™)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e104\u003c\/strong\u003e Patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal Trial Sites\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e25\u003c\/strong\u003e Sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic Footprint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e Countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSub-Study Patients (Newborns to 3 years)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e Patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Duration (Interventional Portion)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48\u003c\/strong\u003e Weeks (Interim Analysis) \/ \u003cstrong\u003e96\u003c\/strong\u003e Weeks (Full Study)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey operational achievements related to the infrastructure include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompletion of enrollment for the pivotal Phase 3 \u003cstrong\u003eTransportNPC™\u003c\/strong\u003e trial.\u003c\/li\u003e\n\u003cli\u003eSuccessful management of a randomized, double-blind, placebo-controlled, parallel group, multicenter study design.\u003c\/li\u003e\n\u003cli\u003eAdministration of \u003cstrong\u003e2,000 mg\/kg\u003c\/strong\u003e doses of Trappsol® Cyclo™ every \u003cstrong\u003e2 weeks\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAlignment with both the FDA and EMA health authority interactions prior to enrollment completion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: Post-Merger Financial Backing and Stability\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The March 26, 2025, merger with Rafael Holdings provides necessary capital to fund operations and the critical 2025 data analysis, overcoming prior liquidity issues (like the Q3 2024 cash balance of approximately \u003cstrong\u003e$0.9 million\u003c\/strong\u003e, or \u003cstrong\u003e$928,010\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003cp\u003eThe financial support context leading up to and through the merger includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePrior financing arrangements with Rafael Holdings since June 2024 totaled \u003cstrong\u003e$16 million\u003c\/strong\u003e in convertible notes.\u003c\/li\u003e\n\u003cli\u003eThe Eighth Amended and Restated Note Purchase Agreement issued a \u003cstrong\u003e$2 million\u003c\/strong\u003e convertible promissory note.\u003c\/li\u003e\n\u003cli\u003eThe merger agreement valued Cyclo Therapeutics shares at \u003cstrong\u003e$0.95\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eRafael Holdings issued shares of its Class B common stock to CYTH shareholders representing approximately \u003cstrong\u003e22%\u003c\/strong\u003e of the combined company.\u003c\/li\u003e\n\u003cli\u003eThe merger exchange ratio was determined to be \u003cstrong\u003e0.3525\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRafael Holdings committed to funding the TransportNPC™ clinical trial through its \u003cstrong\u003e48-week interim analysis\u003c\/strong\u003e, with results expected in the \u003cstrong\u003emiddle of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eValue (Pre-Merger\/At Merger)\u003c\/td\u003e\n\u003ctd\u003eValue (Post-Merger Context)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Cash Balance (Sept 30, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$928,010\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Convertible Notes from RFL (Prior to Closing)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$16 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCYTH Share Valuation in Merger Agreement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.95\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRFL Ownership of Combined Company (Post-Closing)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e22%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerger Exchange Ratio (RFL Class B to CYTH Share)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.3525\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Access to a committed parent company's balance sheet is rare for a clinical-stage biotech facing near-term cash needs, especially following a history of low cash balances, such as the \u003cstrong\u003e$0.9 million\u003c\/strong\u003e reported in Q3 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors cannot easily buy or replicate this specific financial integration, which includes prior investments of \u003cstrong\u003e$5.0 million\u003c\/strong\u003e in stock (June 2023) and subsequent convertible debt financing totaling \u003cstrong\u003e$16 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The merger itself shows management's ability to execute a complex, value-accretive corporate transaction, closing on \u003cstrong\u003eMarch 26, 2025\u003c\/strong\u003e, following shareholder approval on \u003cstrong\u003eAugust 24, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the subsidiary relationship holds, with Rafael Holdings committing resources to fund the TransportNPC™ trial through the \u003cstrong\u003e48-week interim analysis\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: High Gross Margin Potential\n\u003c\/h2\u003e\n\n\u003cp\u003eThe analysis focuses on the potential for high gross margins associated with Cyclo Therapeutics' core asset, Trappsol® Cyclo™.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue: The underlying technology shows a high gross profit margin, suggesting strong unit economics if commercialized.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe reported financial performance for the three months ended September 30, 2024, indicates a high margin potential based on early-stage revenue figures. The gross profit for this period was \u003cstrong\u003e$216,974\u003c\/strong\u003e on total revenues of \u003cstrong\u003e$233,772\u003c\/strong\u003e, equating to an implied gross margin of approximately \u003cstrong\u003e92.81%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod Ended September 30, 2024 (3 Months)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$233,772\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$216,974\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplied Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92.81%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity: High margins are desirable but not guaranteed; this reflects the cost structure of the active ingredient production.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe realized margin reflects the current cost structure for the proprietary formulation, Trappsol® Cyclo™, which is a proprietary formulation of hydroxypropyl beta cyclodextrin.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe active ingredient, Trappsol® Cyclo™, is currently being evaluated for Niemann-Pick Disease Type C1 (NPC) and Alzheimer's disease.\u003c\/li\u003e\n\u003cli\u003eThe company benefits from \u003cstrong\u003eOrphan Drug Designations\u003c\/strong\u003e in the United States and Europe for Trappsol® Cyclo™ in NPC.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability: The cost-of-goods-sold (COGS) structure is proprietary to their manufacturing process.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe ability to maintain low COGS relative to potential pricing is tied to the specific production methodology for the drug substance.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrappsol® Cyclo™ is a \u003cstrong\u003eproprietary formulation\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company announced the commencement of \u003cstrong\u003ecommercial-scale production\u003c\/strong\u003e of batches of Trappsol® Cyclo™ in July 2021.\u003c\/li\u003e\n\u003cli\u003eThe manufacturing process is described as \u003cstrong\u003e'robust, scalable and validated'\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization: The company has demonstrated this margin potential even before achieving full scale.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe margin realization occurred while the company was still in the clinical trial phase, suggesting the cost structure is established prior to peak commercial volume.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company completed enrollment in the Phase 3 TransportNPC™ trial.\u003c\/li\u003e\n\u003cli\u003eSubmission of New Drug Application (NDA) and Marketing Authorization Application (MAA) is targeted for H2 2025.\u003c\/li\u003e\n\u003cli\u003eThe company was engaged in a strategic merger with Rafael Holdings, expected to close before year-end 2024 (based on prior reporting).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage: Sustained, tied directly to the proprietary manufacturing process.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe sustained advantage hinges on the intellectual property surrounding the formulation and the efficiency of the manufacturing process, which dictates the low COGS component of the gross margin calculation.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: Second Indication Pipeline (Early Alzheimer's Disease)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Offers a significant upside scenario, as AD is a vastly larger market than NPC1, even if it is only in Phase 2b.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Metric\u003c\/td\u003e\n\u003ctd\u003eValue\/Period\u003c\/td\u003e\n\u003ctd\u003eSource Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal AD Market (8MM) Forecast 2033\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal AD Market CAGR (2023-2033)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcross eight major markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 7 Markets Value 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 3,194.2 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected to reach USD 4,955.5 Million by 2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Having a second, late-stage asset in a major indication is rare for a company focused on a niche orphan disease.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecond indication asset is in Phase \u003cstrong\u003e2b\u003c\/strong\u003e clinical trial (NCT05607615).\u003c\/li\u003e\n\u003cli\u003eThe primary focus remains on the orphan disease Niemann-Pick Disease Type C1 (NPC1).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: The data and ongoing trial (NCT05607615) are proprietary, but the underlying chemistry is known.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Parameter\u003c\/td\u003e\n\u003ctd\u003eDetail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Identifier\u003c\/td\u003e\n\u003ctd\u003eNCT05607615\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Design\u003c\/td\u003e\n\u003ctd\u003eU.S. multicenter, randomized, placebo-controlled, double-blind, parallel group, 6-month study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Enrollment\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e120\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Arms\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e500 mg\/kg\u003c\/strong\u003e or \u003cstrong\u003e1000 mg\/kg\u003c\/strong\u003e of Trappsol® Cyclo™ and Placebo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: The company is actively pursuing this, showing a dual-track development strategy.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the nine months ended September 30, \u003cstrong\u003e2024\u003c\/strong\u003e, were \u003cstrong\u003e$11,830,127\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, \u003cstrong\u003e2024\u003c\/strong\u003e, were \u003cstrong\u003e$928,010\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the nine months ended September 30, \u003cstrong\u003e2024\u003c\/strong\u003e, was \u003cstrong\u003e$19,157,261\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; the value is contingent on successful Phase 2b results, which are not yet available.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe trial targets the reduction of amyloid beta and tau.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCyclo Therapeutics, Inc. (CYTH) - VRIO Analysis: Regulatory Alignment with FDA and EMA for NPC1\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Positive feedback from both major agencies reduces uncertainty regarding trial design and potential approval requirements for NPC1.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Achieving alignment with both the FDA and EMA on a pivotal rare disease trial is a significant de-risking factor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e This alignment is based on specific interactions and submissions that competitors would have to repeat from scratch.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The team successfully navigated these health authority interactions to complete enrollment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as the established dialogue and understanding with regulators are valuable institutional knowledge.\u003c\/p\u003e\n\u003cp\u003eThe regulatory alignment supports the path to submission based on the 48-week interim analysis of the TransportNPC™ study.\u003c\/p\u003e\n\u003cp\u003eKey trial statistics supporting this alignment include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal Study Enrollment (TransportNPC™)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e104\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubstudy Enrollment (\u0026lt; 3 years)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Completion Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMay 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterim Data Readout Target\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eQ1 2025\u003c\/strong\u003e \/ \u003cstrong\u003eH1 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNDA\/MAA Submission Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2H 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal AEs Reported (as of 6\/30\/24)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e625\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrade 3 (Severe) AEs (as of 6\/30\/24)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe regulatory status is further supported by specific designations:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOrphan Drug Designation (U.S. and EU) for Trappsol\u003csup\u003e®\u003c\/sup\u003e Cyclo™ to treat NPC1.\u003c\/li\u003e\n\u003cli\u003eFast Track Designation in the U.S.\u003c\/li\u003e\n\u003cli\u003eRare Pediatric Disease Designation in the U.S., which is a chief requirement for receiving a Priority Review Voucher (PRV) upon marketing authorization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: The Company ended the third quarter with approximately \u003cstrong\u003e$0.9 million\u003c\/strong\u003e of cash as of September 30, 2024, down from \u003cstrong\u003e$9,246,592\u003c\/strong\u003e at December 31, 2023. The net loss for the three months ended September 30, 2024, was approximately \u003cstrong\u003e$8.8 million\u003c\/strong\u003e ($8,832,944), with Research and Development expenses for the same period at approximately \u003cstrong\u003e$5.5 million\u003c\/strong\u003e ($5,492,844). The Company has borrowed \u003cstrong\u003e$15,000,000\u003c\/strong\u003e from Rafael Holdings through November 12, 2024.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516148572309,"sku":"cyth-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cyth-vrio-analysis.png?v=1740165340","url":"https:\/\/dcf-model.com\/products\/cyth-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}